MIROCALS: breaking down the trial results
Related topics
The MIROCALS trial found no statistically significant survival benefit from low-dose interleukin-2 (IL-2) compared with placebo across the full study group. A post-trial analysis suggested a possible benefit among people with lower levels of the biomarker phosphorylated neurofilament heavy chain (pNFH), but this subgroup finding needs further study.
Why this matters
These results do not establish low-dose IL-2 as an effective treatment for MND. The possible subgroup effect may help guide future research, while the trial also raised a non-significant concern that IL-2 could be harmful in people with higher pNFH levels.
Limitations and context
The trial included 220 recently diagnosed people in the UK and France and followed them for 21 months. The overall result was not statistically significant, and the pNFH findings came from analyses of subgroups after the trial, so they may reflect chance and require confirmation. This account is from an organisational research blog explaining a published Lancet paper, not the primary paper itself.